Physicochemical and biological assays for quality control of biopharmaceuticals: Interferon alfa-2 case study

Biologicals

Volumn 36, Issue 6, 2008, Pages 383-392

  Silva, Marta M C G ^a   Lamarre, Baptiste ^b   Cerasoli, Eleonora ^b   Rakowska, Paulina ^b   Hills, Anna ^b   Bailey, Marc J A ^b   Wheeler, Jun X ^a   Burns, Chris J ^a   Gaines Das, Rose E ^a   Jones, Chris ^a   Robinson, C Jane ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b NATIONAL PHYSICAL LABORATORY   (United Kingdom)

Author keywords

Bioassay; Biopharmaceutical; Dynamic light scattering; Interferon; qRT PCR

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; METHIONINE;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG OXIDATION; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGHT SCATTERING; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REVERSED PHASE LIQUID CHROMATOGRAPHY;

BIOLOGICAL ASSAY; BIOLOGICAL PRODUCTS; CELL PROLIFERATION; CHROMATOGRAPHY; DRUG DESIGN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; METHIONINE; OXYGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECIMEN HANDLING; TEMPERATURE;

EID: 56949099563     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2008.06.003     Document Type: Article

References (27)

1. Chirino A.J., and Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22 (2004) 1383-1391
2. ICH guideline Q6B. Specifications: test procedures and acceptance criteria for biotechnological/biological products. Available from (1999). [accessed March 2008]
3. ICH guideline Q5E. Comparability of biotechnological/biological products subject to changes in their manufacturing process. Available from: (2004). [accessed March 2008
4. Mire-Sluis A.R. Progress in the use of biological assays during the development of biotechnology products. Pharm Res 18 9 (2001) 1239-1246
5. TOPRA. Regulatory rapporteur. Available from: (2006). [accessed March 2008]
6. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 7053 (2005) 967-972
7. Klaus W., Gsell B., Labhardt A.M., Wipf B., and Senn H. The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol 274 4 (1997) 661-675
8. 2b revealed by X-ray crystallography. Structure 4 12 (1996) 1453-1463
9. von Gabain A., Lundgren E., Ohlsson M., Holmgren E., Josephsson S., and Alkan S.S. Three human interferon-α2 subvariants disclosed structural and functional differences. Eur J Biochem 190 2 (1990) 257-261
10. Ruiz L., Reyes N., Aroche K., Báez R., Aldana R., and Hardy E. Some factors affecting the stability of interferon alpha 2b in solution. Biologicals 34 (2006) 15-19
11. Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., et al. Structural and biologic characterization of pegylated recombinant IFN-α2b. J Interferon Cytokine Res 21 12 (2001) 1103-1115
12. Cindrić M., Galić N., Vuletić M., Klarić M., and Drevenkar V. Evaluation of recombinant human interferon α-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal 40 (2006) 781-787
13. Interferon Alfa-2a concentrated solution, monograph 1110. European pharmacopoeia. 5th ed. vol. 2 (2005), Council of Europe, Strasbourg, France 1812-1815
14. Interferon alfa-2a CRS (I0320300) instructions for use. EDQM Pharmaceutical reference standards & preparation database; Available from: , [accessed March 2008].
15. Interferon alfa-2b CRS (I0320301) instructions for use. EDQM Pharmaceutical reference standards & preparation database; Available from: [accessed March 2008]
16. Silva M.M.C.G., Gaines-Das R.E., Jones C., and Robinson C.J. Biological activity of EDQM CRS for interferon alfa-2a and interferon alfa-2b - assessment in two in vitro bioassays. Pharmeuropa Bio 1 (2007) 1-6
17. Interferon alpha-2a (Human rDNA derived, code 95/650) instructions for use. NIBSC catalogue of biological reference materials; Available from: http://www.nibsc.ac.uk/documents/ifu/95-650.pdf [accessed July 2008].
18. Interferon alpha-2b (human rDNA derived, code 95/566) instructions for use. NIBSC catalogue of biological reference materials; Available from: http://www.nibsc.ac.uk/documents/ifu/95-566.pdf, [accessed July 2008].
19. Burns C.J., Silva M.M.C.G., Gray E., and Robinson C.J. Quantitative RT-PCR as an alternative to late-stage bioassays for vascular endothelial growth factor. J Pharm Biomed Anal 45 3 (2008) 460-468
20. Bailey MJAB, Cerasoli E, Gaines Das R, Hills A, Jones C, Kumarswami N, et al. NPL report AS 5, strengthening quality control of biopharmaceutical products through the establishment of structure-function relationships. NPL Publications; Available from: , [accessed July 2008].
21. Holmes D.I.R., and Zachary I. Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett 557 (2004) 93-98
22. Gaines Das R.E., and Tydeman M.S. Iterative weighted regression analysis of logit responses: a computer program for analysis of bioassays and immunoassays. Comput Methods Programs Biomed 15 1 (1982) 13-21
23. Finney D.J. Statistical method in biological assay. 3rd ed. (1978), Griffin, London
24. Robinson C.J., Gaines Das R., and Maile P. The World Health Organization reference reagent for keratinocyte growth factor, KGF. Growth Factors 24 4 (2006) 279-284
25. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289 (2005) 1-30
26. Dynamic light scattering: an introduction in 30 minutes. Malvern technical notes; Available from: http://www.malvern.co.uk/common/downloads/campaign/MRK656-01.pdf, [accessed July 2008].
27. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185 (1999) 129-188